PATZF Stock UPDATES Patrys Ltd Mel (PATZF) 0.0350 09/16/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 16, 2014 at 10:00 PM

Patrys Ltd Mel (PATZF) 0.0350 $PATZF

Global Colon Carcinoma Therapeutics Pipeline Report 2014 - 5 Companies & 15 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sl8zck/colon_carcinoma) has announced the addition of the "Colon Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aposense Ltd. - Teva Pharmaceutical Industries Limited - Patrys Limited - Philogen S.p.A. - AIMM Therapeutics B.V. Drug Profiles - CEP-37250 - PAT-LM1 - ATT-11T - CIGB-247 - Antibody for Oncology - Small Molecules to Inhibit Tubulin for Oncology - Monoclonal Antibody for Colon Carcinoma - methoxynaphthylfenoterol - Vaccine for Lymphoma and Colon Carcinoma - Recombinant Protein to Activate IL-2 Receptor for Oncology - Adhesio-mAb - Anti-MFG-E8 Mab - F8IL-4 - Peptide for Colon Carcinoma - Antibody to Inhibit Rspo2 and Rspo3 for Oncology For more information visit http://www.researchandmarkets.com/research/sl..._carcinoma

Staphylococcus Aureus Infections - Pipeline Review, H2 2013 Report
M2 - Wed Feb 19, 2:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/jg3jt3/staphylococcus) has announced the addition of the "Staphylococcus Aureus Infections - Pipeline Review, H2 2013" report to their offering. 'Staphylococcus Aureus Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Staphylococcus Aureus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections. Scope - A snapshot of the global therapeutic scenario for Staphylococcus Aureus Infections. - A review of the Staphylococcus Aureus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Staphylococcus Aureus Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Staphylococcus Aureus Infections Overview Therapeutics Development Clinical Stage Products Early Stage Products Unknown Stage Products Staphylococcus Aureus Infections - Therapeutics Assessment Drug Profiles lysostaphin - Drug Profile WCK-771 - Drug Profile avarofloxacin hydrochloride - Drug Profile PF-06290510 - Drug Profile P-128 - Drug Profile GSK-2392106A - Drug Profile STEBVax - Drug Profile GSK-2392105A - Drug Profile GSK-2392103A - Drug Profile GSK-2392019A - Drug Profile NDV-3 Vaccine - Drug Profile SASPject PT1.2 - Drug Profile GSK-2392102A - Drug Profile Staphylococcus Aureus Vaccine - Drug Profile MEDI-4893 - Drug Profile MORAb-048 - Drug Profile gallium citrate Ga 67 - Drug Profile Staphylococcus Aureus Vaccine - Drug Profile NVC-727 - Drug Profile SEB-HIG - Drug Profile SEB-HuMab - Drug Profile Bactericidal Venom-Based Polypeptides - Drug Profile MGB-BP-3 - Drug Profile Second Generation Oxas - Drug Profile Novarifyn - Drug Profile AQP-182 - Drug Profile niacinamide - Drug Profile Vaccine For Staphylococcus - Drug Profile and many more..... Featured News & Press Releases Appendix List of Tables List of Figures Some of the Companies Mentioned AstraZeneca PLC GlaxoSmithKline plc Genentech, Inc. Daiichi Sankyo Company, Limited Merck & Co., Inc. Exploit Technologies Pte Ltd Imaxio Novartis AG Actelion Ltd Pfizer Inc. Wockhardt Limited NovaBay Pharmaceuticals, Inc. Patrys Limited Galapagos NV Microbio Co., Ltd. Morphotek, Inc. Bharat Biotech International Limited Novabiotics Ltd GlycoVaxyn AG Priaxon AG Aquapharm Biodiscovery Limited Aridis Pharmaceuticals LLC For more information visit http://www.researchandmarkets.com/research/jg...hylococcus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Colon Cancer - Pipeline Review, H2 2013 Gives Coverage of the Colon Cancer Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Mon Aug 12, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfjngz/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Colon Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Colon Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Colon Cancer. - A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AEterna Zentaris Inc. - Advenchen Laboratories, LLC - Affichem - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Cell Therapeutics, Inc. - Curis, Inc. - Cytokinetics, Inc - DEKK-TEC, Inc. - Eli Lilly and Company - Etubics Corporation - Five Prime Therapeutics, Inc. - Geistlich Pharma AG - ISA Pharmaceuticals B.V. - Isofol Medical AB - Kalos Therapeutics, Inc. - Lorus Therapeutics Inc - MabVax Therapeutics, Inc. - Northwest Biotherapeutics, Inc. - NovaLead Pharma Pvt. Ltd. - OncoMed Pharmaceuticals, Inc. - OncoVista Innovative Therapies, Inc. - Patrys Limited - PharmaMar, S.A. - Pharminox Limited - Pique Therapeutics - Tautatis Incorporated - Telik, Inc. - Transgene Biotek Ltd - Viventia Biotechnolo For more information visit http://www.researchandmarkets.com/research/kf...lon_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fort Riley and Fort Wainwright Get Wi-Fi Boost

Reliable Connectivity for Soldiers: A Strategic Move Wi-Fi probably wouldn't be on top of the list in a battlefield strategy session, but give it a thought—it’s the digital lifeline for our troops off-duty. That’s what’s cooking with the U.S. Army’s big move to amp up reliable Wi-Fi at Fort Riley and Fort Wainwright, thanks to Boldyn Networks and their BaseNet...

LG's ASIL D Certification: A Game Changer in Autos

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Leatt Gears Up for Q3 Results Conference Call

A good heads-up, folks, isn't just about keeping helmets snug—it’s about knowing when to cash in, especially when Leatt Corporation's got their Q3 results ready to drop. November 12 is the big day, so circle that on your calendars. They're rolling out the numbers before the market even gets its coffee, possibly nudging the ticker, OTCQB:LEAT, in a ripple you’ll want...

Cultural Tech Fusion: The Asia-Pacific Way Forward

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Wendy C. Wilson Earns Inner Circle Pinnacle Honor

Leadership Recognized: Wendy C. Wilson's Impact Some folks know their way around the trenches of corporate battle, and Wendy C. Wilson is one of them. Known for her grit and savvy, she now takes a coveted spot in The Inner Circle of Excellence as a Pinnacle Professional Member. This title isn't just for show—it's a hat tip to her powerhouse contributions as a speaker on...

Spatial Genomics Market Set for Major Expansion by 2031

The Rise of Spatial Genomics You’ve got to hand it to the science behind spatial genomics and transcriptomics—this arena’s not just on a hot streak; it’s scorching. We’re staring down the barrel of a market raring to more than double in value, surging from a worth of USD 0.67 billion in 2026 straight to the big USD 1.23 billion in 2031. The CAGR that’s...

PharmaBlock Forum: Strategic CMC Moves Crucial for Biotech

CMC Strategies: The Unsung Hero in Biotech Development Ah, the world of biotech, where one day you're a hero in the lab, and the next you're scrambling to make sense of chemistry, manufacturing, and controls (CMC). It's high time folks started realizing that CMC isn't just procedural drudgery—it's the backbone of making a promising drug go global. That's what the...

Alscan Clinches Three PSA Awards, Sets Industry Standard

Alscan's Triple Trophy Triumph with PSA Network in 2026 Talk about setting the bar high! Alscan snagged not one, not two, but three prestigious awards from the PSA Network—quite a haul for any outfit looking to make waves in the security systems game. The recognition showcases their prowess in custom security solutions, serving businesses and industries with vigilance...

Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...